{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Overall Response Rate (ORR) will be defined as the proportion of patients with a CR or a PR per RECIST v1.1 based upon the best response as assessed; confirmation of response was not required, assessed up to 49 months.","groups":[{"description":"4mg RRx-001 once weekly (QW) until progression, followed by up to 6 cycles of platinum doublet chemotherapy","id":"OG000","title":"RRx-001 + Platinum Doublet (A01-09)"},{"description":"RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).","id":"OG001","title":"RRx-001 + Platinum + RRx-001 (A10)"},{"description":"Standard of Care Investigator's Choice Control Arm, treatment options of one of the following: carboplatin, etoposide, doxil, gemcitabine, vinorelbine or taxane treatments until progression or intolerable toxicity","id":"OG002","title":"Investigator's Choice (A10)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Assessed up to 49 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}